Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
12/9/24 Enanta Pharmaceuticals (ENTA) EDP-938 for Respiratory Syncytial Virus (RSV) Treatment Subscribers Only Subscribers Only Subscribers Only
12/8/24 Novartis (NVS) Scemblix for Chronic Myelogenous Leukemia (CML) Subscribers Only Subscribers Only Subscribers Only
12/8/24 Johnson & Johnson (JNJ) Tecvayli for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
12/7/24 Novo Nordisk (NVO) Etavopivat for Sickle Cell Anemia Subscribers Only Subscribers Only Subscribers Only
12/4/24 Eli Lilly (LLY) Zepbound for Obesity Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
02/29/2024 Subscribers Only Subscribers Only Trial Announcement - Initiation
09/12/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/30/2024 Subscribers Only Subscribers Only Trial Data - Updated Results
10/16/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/26/2024 Subscribers Only Subscribers Only Trial Data - Updated Results